Discontinue Doxepin 75 mg Immediately in This 73-Year-Old Patient with Cognitive Dysfunction
This patient should have doxepin discontinued due to cognitive dysfunction, as the medication is directly implicated in causing confusion and oversedation in elderly patients, and the dose of 75 mg exceeds recommended geriatric dosing.
Why Doxepin Must Be Stopped
The 2019 AGS Beers Criteria explicitly identifies tricyclic antidepressants like doxepin as medications that increase risk of cognitive impairment, delirium, and falls in older adults 1. The FDA label is unequivocal: "Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of Doxepin and observed closely" 2. When cognitive dysfunction appears, this represents a serious adverse effect requiring immediate action.
The Dose is Too High
The current dose of 75 mg is inappropriate for this elderly patient:
- FDA guidance states elderly patients should start at the "low end of the dosing range" 2
- For insomnia specifically, efficacy studies in elderly patients used 1-3 mg doses, not 75 mg 3
- The 75 mg dose is an antidepressant dose, not an insomnia dose, and carries substantially higher anticholinergic burden
Evidence Supporting Discontinuation
Recent case evidence demonstrates cognitive improvement upon doxepin cessation: A 2024 case report showed a 76-year-old woman experienced "significant cognitive improvement following deprescribing long-term use of a strong anticholinergic drug, doxepin" 4. Importantly, she abruptly stopped (despite planned taper) without severe withdrawal effects and had significantly improved cognitive function.
Additional research confirms this pattern: A 2004 study of elderly patients discontinuing anticholinergic medications showed significant improvement in cognitive scores (ADAS-Cog) with no adverse events or emergent symptoms 5.
How to Discontinue Safely
While the case report showed successful abrupt discontinuation 4, the FDA label warns about withdrawal symptoms after prolonged use 2. A cautious taper over 2-4 weeks is prudent:
- Reduce to 50 mg for 1 week
- Then 25 mg for 1 week
- Then discontinue
- Monitor twice weekly for withdrawal symptoms (anxiety, insomnia rebound, gastrointestinal symptoms)
However, if cognitive dysfunction is severe (disorientation, confusion, safety concerns), immediate discontinuation may be warranted given the case evidence of safe abrupt cessation 4.
Alternative Insomnia Management
If insomnia treatment remains necessary after discontinuation:
- Low-dose doxepin (1-3 mg) could be reconsidered only after cognitive function normalizes, as this dose has demonstrated efficacy and safety in elderly patients 3
- Cognitive behavioral therapy for insomnia (CBT-I) is the gold standard and carries no cognitive risk 6, 7
- Suvorexant or ramelteon are safer alternatives with lower anticholinergic burden 6, 7
Critical Pitfalls to Avoid
- Do not continue at current dose hoping symptoms resolve - the FDA explicitly warns that sedating drugs cause confusion in elderly patients 2
- Do not switch to another anticholinergic agent (e.g., diphenhydramine, hydroxyzine) - these carry similar or worse cognitive risks 1
- Do not assume the cognitive dysfunction is unrelated - doxepin's anticholinergic and sedating properties directly cause these symptoms in elderly patients 2
The evidence converges: this dose is inappropriate, the cognitive dysfunction is likely medication-related, and discontinuation offers the best chance for cognitive recovery while minimizing mortality and morbidity risks associated with continued anticholinergic exposure in an elderly patient.